Forum Markets INC (FRMM) — SEC Filings

Overview

Forum Markets INC (FRMM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 10, 2026: FORUM MARKETS Inc. filed an EFFECT form on April 10, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001125, relates to Act 33 and File No. 333-289772. The effectiveness date was April 9, 2026.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Forum Markets INC is neutral.

Filing Type Overview

Forum Markets INC (FRMM) has filed 1 EFFECT, 36 8-K, 1 424B3, 3 10-Q, 2 DEF 14A, 4 8-K/A, 1 DEFA14A, 2 10-K/A with the SEC between Apr 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• FORUM MARKETS Inc. EFFECT Filing Effective — EFFECT · Apr 10, 2026 Risk: low
  FORUM MARKETS Inc. filed an EFFECT form on April 10, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 99999999
• FORUM MARKETS Joins AI Chip Infrastructure Initiative — 8-K · Apr 8, 2026 Risk: medium
  On April 8, 2026, FORUM MARKETS Inc. announced its participation in the AI Chip Infrastructure initiative. The company filed a current report (8-K) detailing th
• Forum Markets Inc. Files 424B3 Prospectus Supplement — 424B3 · Apr 8, 2026 Risk: low
  Forum Markets Inc. filed a 424B3 prospectus supplement on April 8, 2026, related to its securities. The filing is associated with SEC Accession Number 000121390
• FORUM MARKETS Inc. Amends Sales Agreement — 8-K · Apr 8, 2026 Risk: low
  On April 8, 2026, FORUM MARKETS Inc. entered into a Second Amended and Restated Sales Agreement. This agreement amends a previous sales agreement, with the spec
• ETHZilla Corp Files 8-K: Material Agreement Termination — 8-K · Dec 30, 2025 Risk: medium
  On December 30, 2025, ETHZilla Corporation filed an 8-K to report the termination of a material definitive agreement and other events. The company, formerly kno
• ETHZilla Corp Announces Executive & Board Changes — 8-K · Dec 19, 2025 Risk: medium
  On December 19, 2025, ETHZilla Corporation filed an 8-K report detailing changes in its executive team and board of directors. The filing includes information o
• 8-K Filing — 8-K · Dec 16, 2025
• 8-K Filing — 8-K · Dec 10, 2025
• ETHZilla Corp Completes Acquisition, Changes Name — 8-K · Dec 3, 2025 Risk: medium
  On December 2, 2025, ETHZilla Corporation entered into a material definitive agreement related to the completion of an acquisition. The company, formerly known
• ETHZilla Corp Reports Director/Officer Changes & Compensatory Arrangements — 8-K · Dec 1, 2025 Risk: medium
  On December 1, 2025, ETHZilla Corporation filed an 8-K report detailing changes in its board of directors and executive officers, as well as updates to compensa
• 8-K Filing — 8-K · Nov 25, 2025
• ETHZilla Pivots to Crypto, Reports Massive Loss Amid Fundraising Spree — 10-Q · Nov 14, 2025 Risk: high
  ETHZilla Corp (FRMM) reported a significant strategic shift and substantial financial changes for the nine months ended September 30, 2025. The company generate
• ETHZilla Seeks Shareholder Nod to Lift Convertible Note Cap — DEF 14A · Nov 4, 2025 Risk: medium
  ETHZilla Corp (FRMM) is holding a virtual special meeting on December 16, 2025, at 9:00 am Pacific Time to seek stockholder approval for a critical financing me
• ETHZilla Corp. Files 8-K: Regulation FD & Financials — 8-K · Oct 29, 2025 Risk: low
  On October 29, 2025, ETHZilla Corp. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. ETHZilla
• ETHZilla Corp. Files 8-K with Financials — 8-K · Oct 27, 2025 Risk: low
  On October 27, 2025, ETHZilla Corp. filed an 8-K report. The filing indicates a change in its reporting status and includes financial statements and exhibits. T
• ETHZilla Corp. Completes Acquisition, Enters Material Agreement — 8-K · Oct 23, 2025 Risk: medium
  On October 22, 2025, ETHZilla Corp. (formerly 180 Life Sciences Corp. and KBL Merger Corp. IV) entered into a material definitive agreement and completed an acq
• ETHZilla Corp Files 8-K on Security Holder Rights & Bylaws — 8-K · Oct 15, 2025 Risk: medium
  ETHZilla Corporation filed an 8-K on October 15, 2025, reporting events as of October 14, 2025. The filing indicates material modifications to security holder r
• ETHZilla Corp. Files 8-K with Key Corporate Updates — 8-K · Oct 8, 2025 Risk: medium
  ETHZilla Corp. filed an 8-K on October 8, 2025, reporting several key events. These include material modifications to security holder rights, changes in officer
• ETHZilla Corp Files 8-K Report — 8-K · Sep 30, 2025 Risk: medium
  On September 30, 2025, ETHZilla Corporation filed an 8-K report. The filing indicates a change in the company's structure or operations, as it is listed under '
• ETHZilla Corp. Files 8-K/A Amendment — 8-K/A · Sep 25, 2025 Risk: medium
  ETHZilla Corp. filed an amendment (8-K/A) on September 25, 2025, related to events occurring on September 22, 2025. The filing indicates a material definitive a
• ETHZilla Corp. Files 8-K: Material Agreements & Equity Sales — 8-K · Sep 22, 2025 Risk: medium
  ETHZilla Corp. entered into a material definitive agreement on September 22, 2025, which also created a direct financial obligation. The company also disclosed
• ETHZilla Corp Files Definitive Additional Materials — DEFA14A · Sep 19, 2025 Risk: low
  ETHZilla Corporation filed definitive additional materials on September 19, 2025, related to its proxy statement. The filing indicates no fee was required for t
• ETHZilla Corp. Files 8-K, Shifts Focus to Crypto Assets — 8-K · Sep 15, 2025 Risk: medium
  On September 15, 2025, ETHZilla Corp. filed an 8-K report. The filing indicates a change in its business focus, previously operating as 180 Life Sciences Corp.
• ETHZilla Corp. Enters Material Definitive Agreement — 8-K · Sep 8, 2025 Risk: medium
  On September 5, 2025, ETHZilla Corp. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as 180 Li
• ETHZilla Corp. Files 8-K on Material Agreements & Officer Changes — 8-K · Sep 5, 2025 Risk: medium
  ETHZilla Corp. (formerly 180 Life Sciences Corp.) filed an 8-K on September 5, 2025, reporting on several material events as of September 2, 2025. These include
• ETHZilla Corp to Acquire 03 Life Sciences — 8-K · Sep 2, 2025 Risk: medium
  ETHZilla Corporation (formerly 180 Life Sciences Corp.) announced on August 28, 2025, that it has entered into a definitive agreement to acquire all outstanding
• ETHZilla Corp. Enters Material Definitive Agreement — 8-K · Aug 25, 2025 Risk: medium
  On August 22, 2025, ETHZilla Corp. (formerly 180 Life Sciences Corp. and KBL Merger Corp. IV) entered into a material definitive agreement. The company, incorpo
• ETHZilla Corp. Files 8-K/A Amendment with Key Corporate Updates — 8-K/A · Aug 21, 2025 Risk: medium
  ETHZilla Corp. filed an amendment (8-K/A) on August 21, 2025, related to events occurring on August 7, 2025. The filing indicates several material events includ
• ETHZilla Corp Files 8-K/A Amendment — 8-K/A · Aug 18, 2025 Risk: medium
  ETHZilla Corp filed an 8-K/A amendment on August 18, 2025, related to events occurring on July 31, 2025. The filing pertains to material definitive agreements,
• 180 Life Sciences Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 14, 2025 Risk: medium
  On August 13, 2025, 180 Life Sciences Corp. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity s
• 180 Life Sciences Files 8-K on Equity Sales & Bylaw Changes — 8-K · Aug 13, 2025 Risk: medium
  180 Life Sciences Corp. filed an 8-K on August 13, 2025, reporting unregistered sales of equity securities and amendments to its articles of incorporation or by
• 180 Life Sciences Corp. Files 8-K Report — 8-K · Aug 12, 2025 Risk: low
  On August 12, 2025, 180 Life Sciences Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial s
• 180 Life Sciences Corp. Files 8-K with Key Corporate Updates — 8-K · Aug 11, 2025 Risk: medium
  On August 7, 2025, 180 Life Sciences Corp. entered into a material definitive agreement, likely related to its common stock and warrants. The company also repor
• 180 Life Sciences Corp. Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Aug 5, 2025 Risk: medium
  On July 31, 2025, 180 Life Sciences Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• 8-K Filing — 8-K · Jul 30, 2025
• 180 Life Sciences Corp. Files 8-K with Corporate Updates — 8-K · Jul 24, 2025 Risk: medium
  On July 24, 2025, 180 Life Sciences Corp. filed an 8-K report detailing several key events. These include material modifications to security holder rights, chan
• 180 Life Sciences Posts No Revenue, Focuses on Clinical Trials — 10-Q · Jul 23, 2025 Risk: high
  180 Life Sciences Corp. (FRMM) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage biotechnology company. Th
• 180 Life Sciences Corp. Files 8-K on Executive and Director Changes — 8-K · Jul 14, 2025 Risk: medium
  On July 11, 2025, 180 Life Sciences Corp. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also addresses comp
• 180 Life Sciences Sets Virtual Annual Meeting for July 24 — DEF 14A · Jul 7, 2025 Risk: low
  180 Life Sciences Corp. (FRMM) filed a Definitive Proxy Statement (DEF 14A) on July 7, 2025, for its annual meeting scheduled for July 24, 2025, at 9:00 a.m. Pa
• 180 Life Sciences Corp. Files 8-K Report — 8-K · Jul 1, 2025 Risk: low
  On July 1, 2025, 180 Life Sciences Corp. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mat
• 180 Life Sciences Corp. Files 8-K/A Amendment — 8-K/A · Jun 30, 2025 Risk: medium
  180 Life Sciences Corp. filed an amendment (8-K/A) on June 30, 2025, to a report originally dated June 12, 2025. The amendment addresses the entry into and term
• 180 Life Sciences Files 8-K on Shareholder Nominations — 8-K · Jun 25, 2025 Risk: low
  On June 25, 2025, 180 Life Sciences Corp. filed an 8-K report detailing shareholder nominations for its board of directors and other events. The company, previo
• 180 Life Sciences Corp. Files 8-K on Equity Sales — 8-K · Jun 20, 2025 Risk: medium
  On June 17, 2025, 180 Life Sciences Corp. reported on the unregistered sale of equity securities and other events. The company, formerly known as KBL Merger Cor
• 180 Life Sciences Corp. Files 8-K with Agreement Termination, Director Changes — 8-K · Jun 18, 2025 Risk: medium
  On June 12, 2025, 180 Life Sciences Corp. reported on several key events including the termination of a material definitive agreement and changes in its board o
• 180 Life Sciences Corp. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  180 Life Sciences Corp. filed its quarterly report (10-Q) for the period ending March 31, 2025. The company, formerly known as KBL Merger Corp. IV, is incorpora
• 180 Life Sciences Corp. Files 10-K Amendment — 10-K/A · May 8, 2025 Risk: low
  180 Life Sciences Corp. filed an amendment (No. 2) to its Form 10-K for the fiscal year ended December 31, 2024. The company, previously known as KBL Merger Cor
• 180 Life Sciences Corp. Files 8-K Report — 8-K · May 1, 2025 Risk: low
  On May 1, 2025, 180 Life Sciences Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company,
• 180 Life Sciences Corp. Files 8-K for Material Agreement — 8-K · Apr 30, 2025 Risk: medium
  On April 28, 2025, 180 Life Sciences Corp. entered into a material definitive agreement. The company, formerly known as KBL Merger Corp. IV, is incorporated in
• 180 Life Sciences Corp. Files 2024 10-K Amendment — 10-K/A · Apr 25, 2025 Risk: low
  180 Life Sciences Corp. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as KBL Merger
• 180 Life Sciences Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 9, 2025 Risk: medium
  On April 6, 2025, 180 Life Sciences Corp. entered into a material definitive agreement. The company also reported unregistered sales of equity securities and fi

Risk Profile

Risk Assessment: Of FRMM's 46 recent filings, 2 were flagged as high-risk, 30 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Forum Markets INC's most recent 10-Q filing (Nov 14, 2025):

• Revenue: $4,110,169
• Net Income: -$220,837,892
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $53,309,509
• Operating Margin: N/A
• Total Assets: $1,009,312,988
• Total Debt: $500,000,805

Key Executives

• McAndrew Rudisill
• Board of Directors

Industry Context

The digital asset and blockchain industry is characterized by rapid innovation, high volatility, and an evolving regulatory landscape. Companies in this space often pivot business models to capitalize on new opportunities, such as staking and incentive programs. Competition is fierce, with established players and new entrants constantly vying for market share and technological advancement.

Top Tags

corporate-governance (12) · material-agreement (10) · equity-sale (8) · amendment (6) · filing (5) · pharmaceuticals (5) · management-change (4) · definitive-agreement (4) · corporate-action (4) · 8-K (4)

Key Numbers

• File Number: 333-289772 — SEC registration file number
• Effectiveness Date: 2026-04-09 — Date registration statement became effective
• Prospectus Supplement Size: 287181 — Size of the primary document filed.
• Complete Submission Text File Size: 315734 — Total size of the submission in bytes.
• Revenue: $4.11M — First-time revenue for the nine months ended September 30, 2025, up from $0 in 2024.
• Net Loss: $(220.84M) — Significantly widened for the nine months ended September 30, 2025, from $(1.89M) in 2024.
• General and Administrative Expenses: $227.95M — Massive increase for the nine months ended September 30, 2025, from $3.47M in 2024.
• Cash and Cash Equivalents: $53.31M — Increased from $4.57M at December 31, 2024.
• Total Assets: $1.01B — Jumped from $12.76M at December 31, 2024, driven by digital assets and staking receivables.
• Restricted Cash Equivalents: $505.59M — New asset category as of September 30, 2025.
• Digital Assets: $180.93M — New asset category as of September 30, 2025.
• Staking Receivables: $257.60M — New asset category as of September 30, 2025.
• Convertible Debt: $496.28M — New liability as of September 30, 2025, a primary source of financing.
• Shares Outstanding: 21,398,839 — As of November 12, 2025, reflecting a reverse stock split.
• Special Meeting Date: December 16, 2025 — Date of the virtual special meeting for stockholders

Related Companies

ETHZ · ATNF · ATNFW

Frequently Asked Questions